Findings

The sodium content of packaged foods and beverages purchased by Americans has decreased substantially over the past several years, reports a study in JAMA Internal Medicine.

Early diabetic kidney disease (DKD)—often clinically expressed as proteinuria—is associated with a 16-year reduction in life expectancy, reports a study from Taiwan in Kidney International.

Glycated hemoglobin (HbA1c) levels may underestimate mean glucose level in African Americans with type 1 diabetes, reports a study in Annals of Internal Medicine.

A revised Kidney Donor Risk Index (KDRI) incorporating APOL1 genotype rather than race improves prediction of allograft survival of kidneys from African American deceased donors, reports a study in American Journal of Transplantation.

The study included data on 622 African American deceased kidney donors from three southern US centers. The researchers used a series of models to analyze the impact of a revised KDRI substituting APOL1 genotype for race.

Particularly in interaction with donor age and pathway of death, total ischemic times of 14 hours or longer are associated with increased rates of adverse allograft outcomes in deceased donor kidney recipients, reports a study in Transplantation.

Especially in combination, quarter-dose medication regimens may provide a safe and effective alternative for blood pressure-lowering therapy, according to a meta-analysis in Hypertension.

Pediatric nephrology centers vary in their use of growth hormone therapy for children with chronic kidney disease (CKD) and short stature, reports a study in BMC Nephrology.

Early experience under the revised kidney allocation system (KAS) shows continued quick access to high-quality deceased-donor organs for prior living donors (PLDs), reports a study in the American Journal of Transplantation.

The percentage of Americans with normal body weight but cardiometabolic abnormalities is higher in racial/ethnic minority groups—especially South Asians and Hispanics, reports a study in Annals of Internal Medicine.

A targeted-release formulation of budesonide—designed to deliver drug to the distal ileum—reduces proteinuria in patients with IgA nephropathy who don’t respond to first-line treatment, reports a trial in The Lancet.

Pages